PT  - JOURNAL ARTICLE
AU  - Wilson, Nick
AU  - Summers, Jennifer A
AU  - Ait Ouakrim, Driss
AU  - Hoek, Janet
AU  - Edwards, Richard
AU  - Blakely, Tony
TI  - Improving on estimates of the potential relative harm to health from using modern ENDS (vaping) compared to tobacco smoking
AID  - 10.1101/2020.12.22.20248737
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2020.12.22.20248737
4099  - http://medrxiv.org/content/early/2021/06/27/2020.12.22.20248737.short
4100  - http://medrxiv.org/content/early/2021/06/27/2020.12.22.20248737.full
AB  - Background Although the harm to health from electronic nicotine delivery systems (ENDS) compared to smoked tobacco remains highly uncertain, society and governments still need to know the likely range of the relative harm to inform regulatory policies for ENDS and smoking.Methods We identified biomarkers with specificity of association with different disease groupings e.g., volatile organic compound (VOCs) for chronic obstructive pulmonary disease; and tobacco-specific N’-nitrosamines (TSNAs) and polycyclic aromatic hydrocarbons (PAHs) for all cancers. We conducted a review of recent studies (post January 2017) that compared these biomarkers between people exclusively using ENDS and those exclusively smoking tobacco. The percentage differences in these biomarkers, weighted by study size and adjusted for acrolein from other sources, were used as a proxy for the assumed percentage difference in disease harm between ENDS and smoking. These relative differences were applied to previously modelled estimates of smoking-related health loss (in health-adjusted life-years; HALYs).Results The respective relative biomarker levels (ENDS vs smoking) were: 28% for respiratory diseases (five results, three studies); 42% for cancers (five results, four studies); and 35% for cardiovascular (seven results, four studies). When integrated with the HALY impacts by disease, the overall harm to health from ENDS was estimated to be 33% that of smoking.Conclusions This analysis, suggests that the use of modern ENDS devices (vaping) could be a third as harmful to health as smoking in a high-income country setting. But this estimate is based on a limited number of biomarker studies and is best be considered a likely upper level of ENDS risk given potential biases in our method (i.e., the biomarkers used being correlated with more unaccounted for toxicants in smoking compared to with using ENDS).Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work had funding support from the Cancer Society of New Zealand (Research Contract: Collaboration for Cancer Research Aotearoa New Zealand (CCR)).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Not relevant to this analysis study that only utilised published (anonymised) patient data.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll the relevant data is in the manuscript and Supplementary Information file.3-HPMA3-hydroxypropylmercapturic acidCEMA2-cyanoethylmercapturic acidCOcarbon monoxideCOHbCarboxyhaemoglobinCOPDChronic obstructive pulmonary diseaseCVDCardiovascular diseaseeCOExhaled carbon monoxideENDSElectronic nicotine delivery systemsHALYHealth-adjusted life-yearsHMPMA3-hydroxy-1-methylpropylmercapturic acidNNAL(4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol)NNNN-nitrosonornicotinePAHPolycyclic aromatic hydrocarbonsPheTPhenanthrene tetraolRCTRandomised controlled trialTSNAsTobacco-specific N’-nitrosaminesVOCsVolatile organic compoundsWHOWorld Health Organization